Skip to main content

Table 3 Association of AGO2 haplotypes and breast cancer survival

From: Common genetic polymorphisms of microRNA biogenesis pathway genes and breast cancer survival

   Disease-free survival      Overall survival  
Haplotype Relapse, N (%) No relapse, N (%) aHR (95 % CI) a P Death, N (%) Alive, N (%) aHR (95 % CI) b P
G-A-T-C-A 22 (25.9) 152 (39.9) 1 (reference)   9 (20.9) 167 (38.8) 1 (reference)  
C-A-T-C-G 24 (28.2) 100 (26.3) 1.29 (0.71-2.34) 0.411 13 (30.2) 113 (26.2) 1.73 (0.72-4.13) 0.217
G-A-T-C-G 27 (31.8) 63(16.5) 2.66 (1.49-4.73) 0.001 15 (34.9) 78 (18.1) 3.11 (1.34-7.23) 0.008
G-A-C-C-A 5 (5.9) 12 (3.2) 1.76 (0.66-4.71) 0.262 2 (4.65) 16 (3.7) 2.22 (0.47-10.6) 0.316
Others 7 (8.24) 54 (14.2) 0.66 (0.28-1.56) 0.343 4 (9.3) 57 (13.2) 1.02 (0.31-3.33) 0.978
Total 85 (100) 381 (100)    43 (100) 431 (100)   
  1. NOTE The AGO2 haplotype was composed of five SNPs in order of rs2292779, rs3864659, rs7016981, rs7824304, rs11786030.
  2. a Adjusted for age, tumor size (≤2 cm and >2 cm), lymph-node involvement (no and yes), histologic grade (I-II and III), nuclear grade (I-II and III) and ER status (positive and negative), PR status (positive and negative) and hormone receptor therapy (yes and no).
  3. b Adjusted for age, tumor size (≤2 cm and >2 cm), lymph-node metastasis (no and yes), metastasis (no and yes), histologic grade (I-II and III), and hormone receptor therapy (yes and no).